Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 7/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 4/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.33 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 3/20 | 0.31 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL1602523 | 0.93 | S1PR1 (0.43) | S1PR1S1PR3FFAR1KCNH2CYP26A1 | |
| SCHEMBL12269270 | 0.87 | S1PR1 (0.48) | S1PR1S1PR3FFAR1KCNH2CYP26A1 | |
| Trifluoroacetic Acid SCHEMBL5140105 | 0.83 | S1PR1 (0.55) | S1PR1S1PR3KCNH2 | |
| SCHEMBL1601401 | 0.68 | S1PR1 (0.52) | S1PR1S1PR3FFAR1KCNH2CYP26A1 | |
| SCHEMBL1601244 | 0.65 | S1PR1 (0.52) | S1PR1S1PR3FFAR1KCNH2CYP26A1 | |
| SCHEMBL2084881 | 0.65 | S1PR1 (0.49) | S1PR1S1PR3FFAR1KCNH2CYP26A1 | |
| SCHEMBL1602329 | 0.64 | S1PR1 (0.53) | S1PR1S1PR3FFAR1KCNH2CYP26A1 | |
| SCHEMBL1601933 | 0.63 | S1PR1 (0.48) | S1PR1S1PR3FFAR1KCNH2CYP26A1 | |
| SCHEMBL12269279 | 0.62 | S1PR1 (0.68) | S1PR1S1PR3FFAR1KCNH2MAOB | |
| SCHEMBL1602525 | 0.62 | S1PR1 (0.46) | S1PR1S1PR3FFAR1KCNH2CYP26A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064677-A9 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2008-03-13 | — | — | US | claimed |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | PREDIX PHARMACEUTICAL HOLDINGS | 2007-07-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064677-A9 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 5/4885FFAR1 31/4885 |
| US-20070173487-A1 | S1P receptor modulating compounds and use thereof | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885S1PR3 5/4885FFAR1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.